Holly Cranmer
21c Consultancy (United Kingdom)(GB)
Publications by Year
Research Areas
Health Systems, Economic Evaluations, Quality of Life, Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Cancer Genomics and Diagnostics
Most-Cited Works
- → A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments(2019)67 cited
- → Cost-effectiveness of home-based cardiac rehabilitation: a systematic review(2023)33 cited
- → A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology(2020)29 cited
- → The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective(2022)6 cited
- → Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer(2022)6 cited
- → Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L(2022)5 cited
- → Including carer health-related quality of life in NICE health technology assessments in the United Kingdom(2024)4 cited
- → Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin(2022)3 cited
- → Health-Related Quality of Life in Opioid use Disorder Measured by Utilities: A Systematic Literature Review(2016)2 cited
- → An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology(2023)2 cited